Citation Impact
Citing Papers
Pathophysiology of Migraine: A Disorder of Sensory Processing
2017 Standout
Head and neck squamous cell carcinoma
2020 Standout
NeuPSIG guidelines on neuropathic pain assessment
2010 Standout
High-Affinity Partial Agonists of the Vanilloid Receptor
2003
Functional Properties of the High-Affinity TRPV1 (VR1) Vanilloid Receptor Antagonist (4-Hydroxy-5-iodo-3-methoxyphenylacetate ester) Iodo-Resiniferatoxin
2002
Neural mechanism underlying acupuncture analgesia
2008 Standout
TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia
2004
Firefly luciferase mutants as sensors of proteome stress
2011
Descending control of pain
2002 Standout
4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists
2004
Mechanical, thermal and formalin-induced nociception is differentially altered in 5-HT1A−/−, 5-HT1B−/−, 5-HT2A−/−, 5-HT3A−/− and 5-HTT−/− knock-out male mice
2007 StandoutNobel
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Locomotor networks are targets of modulation by sensory transient receptor potential vanilloid 1 and transient receptor potential melastatin 8 channels
2009 StandoutNobel
A Bivalent Tarantula Toxin Activates the Capsaicin Receptor, TRPV1, by Targeting the Outer Pore Domain
2010 StandoutNobel
The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept
2007 Standout
Translational genomics of nasopharyngeal cancer
2019
Enzymatic assembly of carbon–carbon bonds via iron-catalysed sp3 C–H functionalization
2018 StandoutNatureNobel
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
TRPV1 structures in distinct conformations reveal activation mechanisms
2013 StandoutNatureNobel
Anti-arthritic agents: Progress and potential
2015
Lipopolysaccharide fever is initiated via a capsaicin‐sensitive mechanism independent of the subtype‐1 vanilloid receptor
2004
Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic Implications
2013
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action
2016 StandoutNatureNobel
Catalytic asymmetric synthesis of chromenes and tetrahydroquinolines via sequential allylic alkylation and intramolecular Heck coupling
2012 StandoutNobel
A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain
2015
Transient Receptor Potential Cation Channels in Disease
2007 Standout
The Super-Cooling Agent Icilin Reveals a Mechanism of Coincidence Detection by a Temperature-Sensitive TRP Channel
2004 StandoutNobel
Discovery of Potent, Orally Available Vanilloid Receptor-1 Antagonists. Structure−Activity Relationship of N-Aryl Cinnamides
2004
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Gastrointestinal pain in functional bowel disorders: sensory neurons as novel drug targets
2004
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
Recent advances in the stereoselective synthesis of trans-3,4-disubstituted-piperidines: applications to (−)-paroxetine
2008
Enzymatic resolution of (±)-trans-4-(4′-fluorophenyl)-6-oxo-piperidin-3-ethyl carboxylate, an intermediate in the synthesis of (−)-Paroxetine
2002
Advances in the Chemistry of Tetrahydroquinolines
2011 Standout
Resiniferatoxin Binds to the Capsaicin Receptor (TRPV1) near the Extracellular Side of the S4 Transmembrane Domain
2004
Small molecule probes to quantify the functional fraction of a specific protein in a cell with minimal folding equilibrium shifts
2014 StandoutNobel
Improvement of enzyme activity, stability and selectivity via immobilization techniques
2007 Standout
Design of Potent, Orally Available Antagonists of the Transient Receptor Potential Vanilloid 1. Structure−Activity Relationships of 2-Piperazin-1-yl-1H-benzimidazoles
2006
Metalated Heterocycles and Their Applications in Synthetic Organic Chemistry
2004
Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health
2020 Standout
Functional Oligothiophenes: Molecular Design for Multidimensional Nanoarchitectures and Their Applications
2009 Standout
AN INTRODUCTION TO TRP CHANNELS
2005 Standout
Pyrrole: a resourceful small molecule in key medicinal hetero-aromatics
2015 Standout
Prescribed drugs containing nitrogen heterocycles: an overview
2020 Standout
Sequential mono-N-arylation of piperazine nitrogens. Part 1: A simplified method and its application to the preparation of a key N,N′-biaryl piperazine antifungal intermediate
1999
Works of Mark E. McDonnell being referenced
7-Hydroxynaphthalen-1-yl-urea and -amide antagonists of human vanilloid receptor 1
2003
Diclofenac potassium liquid-filled soft gelatin capsules for the treatment of postbunionectomy pain
2010
Novel inhibitors of heat shock protein Hsp70-mediated luciferase refolding that bind to DnaJ
2012
Riluzole prodrugs for melanoma and ALS: Design, synthesis, and in vitro metabolic profiling
2012
Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors
2014
Synthesis and in vitro evaluation of a novel iodinated resiniferatoxin derivative that is an agonist at the human vanilloid VR1 receptor
2002
Orally Active Benzamide Antipsychotic Agents with Affinity for Dopamine D2, Serotonin 5-HT1A, and Adrenergic α1Receptors
1998
Design and Synthesis of Thrombin Inhibitors: Analogues of MD-805 with Reduced Stereogenicity and Improved Potency
1999
α2 Adrenoceptor Agonists as Potential Analgesic Agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene as a High-Affinity Ligand for the α2D Adrenergic Receptor
2000
The synthesis and evaluation of the major metabolites of mazapertine
1997
α2 Adrenoceptor Agonists as Potential Analgesic Agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene as a High-Affinity Ligand for the α2D Adrenergic Receptor
2000
Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth
2019